Physician profile
Michael Michael Gunter
NPI 1780765669
$4,842.97
in general payments reported to CMS, 2019-2025
39 companies · $662 in 2025
The $662 reported for 2025 was more than what 78% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $988 · 2020: $879 · 2021: $487 · 2022: $465 · 2023: $687 · 2024: $675 · 2025: $662.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,024.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,024.03 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $568.89 | 2019-2024 | Mounjaro, Jardiance, Emgality |
| Novo Nordisk INC | $404.63 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Glaxosmithkline, LLC. | $378.15 | 2020-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Novartis Pharmaceuticals Corporation | $353.95 | 2019-2023 | |
| Astrazeneca Pharmaceuticals LP | $346.96 | 2019-2025 | Farxiga, Airsupra |
| Sanofi-Aventis U.S. LLC | $345.38 | 2019-2024 | |
| Pfizer INC. | $261.05 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $244.08 | 2020-2025 | Capvaxive, Gardasil 9 |
| Amgen INC. | $207.60 | 2019-2023 | Repatha |
| Janssen Pharmaceuticals, INC | $153.08 | 2020-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $147.04 | 2019-2025 | Jardiance |
| Xeris Pharmaceuticals, INC. | $139.85 | 2022-2025 | Gvoke Hypopen |
| Abbott Laboratories | $137.80 | 2023-2025 | Freestyle Libre 3 |
| Regeneron Healthcare Solutions, INC. | $121.86 | 2019 | |
| Abbvie INC. | $106.97 | 2020-2023 |
Show all 39 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Gunter listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.